{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:26:42Z","timestamp":1792762002460,"version":"4.5.0"},"reference-count":6,"publisher":"S. Karger AG","issue":"9","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Background: According to recently published data, low total IgE, elevated IgG-anti-TPO, and a high IgG-anti-TPO\/total IgE ratio are good biomarkers for subtype IIb autoimmune chronic spontaneous urticaria (CSU), which is frequently refractory to antihistamines and omalizumab. Objectives: The aim of the study was to evaluate IgG-anti-TPO\/total IgE ratio\u2019s utility in omalizumab response prediction. Methods: Retrospective study of CSU patients treated with omalizumab at a UCARE between January 2009 and February 2022. Patients were grouped according to response in the first 16 weeks of treatment: responders UAS7 &amp;lt; 7 versus partial\/non-responders UAS7\u22657. Total IgE, IgG-anti-TPO, and IgG-anti-TPO\/total IgE ratio were compared. Other inflammatory biomarkers \u2013 eosinophils, basophils, C-reactive protein, erythrocyte sedimentation rate, and d-dimer \u2013 were analyzed. Statistical analysis: SPSS\u00ae (v25.0), p &amp;lt; 0.05 statistically significant. Results: Total of 175 patients, 140 (80%) women, median age 49 [9\u201388] years, mean CSU duration pre-omalizumab 5.6 \u00b1 8.2 [0\u201354] years, omalizumab duration 3.2 \u00b1 2.5 [0\u201312] years. 116 (66%) had angioedema, 77 (44%) inducible chronic urticaria, 60 (34%) atopy, 24 (14%) autoimmune disease. With omalizumab 300 mg q4 weeks, 69% were responders and 31% partial\/non-responders. Although not reaching significant differences, mean total IgE values were lower and mean IgG-anti-TPO values were higher in partial\/non-responders versus responders (152 vs. 242 kU\/L, p = 0.207, and 38.3 vs. 25.7 U\/mL, p = 0.408, respectively). A higher IgG-anti-TPO\/total IgE ratio was significantly associated with poorer response to omalizumab (p = 0.040). A cut-off &amp;gt;0.154 increased 10 times the odd of poorer response [95% CI 4.62\u201322], AUC 0.872, p &amp;lt; 0.001, with 87.7% sensitivity, although the low specificity (22.4%) does not allow the assumption of response with values &amp;lt;0.154. Other laboratory biomarkers did not show significant differences between partial\/non-responders versus responders. Conclusions: A high IgG-anti-TPO\/total IgE ratio was a good biomarker of poor response to omalizumab in our CSU cohort, with a cut-off &amp;gt;0.154 increasing 10 times the odd of poorer response.<\/jats:p>","DOI":"10.1159\/000532021","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T17:01:27Z","timestamp":1691600487000},"page":"866-869","source":"Crossref","is-referenced-by-count":20,"title":["Anti-TPO IgG\/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria"],"prefix":"10.1159","volume":"184","author":[{"given":"Rita","family":"Br\u00e1s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Esteves Caldeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Bernardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.07.043"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15090"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/all.13586"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.03.049"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/all.13949"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9856843"}],"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/iaa\/article-pdf\/184\/9\/866\/3995801\/000532021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/iaa\/article-pdf\/184\/9\/866\/3995801\/000532021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:31:53Z","timestamp":1745407913000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000532021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":6,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,4]]},"published-print":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1159\/000532021","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}